PATHOGENETIC EFFECTS IN THE TREATMENT OF COMBINED CARDIORESPIRATORY PATHOLOGY
Clinical medicine

PATHOGENETIC EFFECTS IN THE TREATMENT OF COMBINED CARDIORESPIRATORY PATHOLOGY

Published 2019-02-06

Authors:

R.I. Yatsyshyn
P.R. Herych
O.M. Didushko
O.A. Shapoval

Abstract:
Study of the possibility to correct endothelial dysfunction (ED), structural changes in peripheral arteries and synthesis of metabolic-waste products of nitric oxide (NO) (nitrites NO_2^- / nitrates NO_3^-) by means of including the combination of roflumilast and quercetin to the background therapy has been investigated. In 6 months, the use of complex therapy, in contrast to the background one, has resulted in a statistically significant increase of the initial rate by 18.76% from (0.61 ± 0.04) m/s to (0.75 ± 0.04) m/s (t=2.47; p<0.05) and in a statistically significant decrease of the initial diameter of a brachial artery to 3.74 ± 0.28 mm (t=2.49; p<0.05). Administration of complex therapy after 6 months has showed that the concentration of NO metabolites in the blood has gone up 1.3 times, up to 10.35 ± 1.89 mcmole/l (t=1.00; p>0.1) with the norm of 12.05 ± 2.11 mcmole/l. Administration of complex therapy for patients with a severe stage of chronic obstructive pulmonary disease (COPD) in an exacerbation phase accompanied with a stable coronary artery disease and stable effort angina (SCAD SEA) of the 2nd FC helps restore endothelial function, improves peripheral arterial structural changes and has a stimulating effect on the synthesis of NO.
Keywords:
stable coronary artery disease chronic obstructive pulmonary disease endothelial dysfunction oxidative stress
References:
  1. Berezin AE. Terapevticheskiy potentsial α-lipoievoi (tioktovoi) kisloty pri kardiovaskuliarnykh zabolievaniiakh. Ukr. med. chasopys. 2017; 2(118): 95-98. [in Russian]
  2. Berezin AE. Proteiny vnekletochnogo matrixa kak biomarkery vaskuliarnogo remodilirovaniia i kardiovaskuliarnukh klinicheskikh iskhodov. Ukr. med. chasopys. 2015; 6(110): 58-64. [in Russian]
  3. Astuti RI, Nasuno R, Takagi H. Nitric oxide signaling in yeast. Appl. Microbiol. Biotechnol. 2016; 100(22): 9483-9497.
  4. Byon CH, Heath JM, Chen Y. Redox signaling in cardiovascular pathophysiology: a focus on hydrogen peroxide and vascular smooth muscle cells. Redox. Biol. 2016; 9: 244-253.
  5. Chen Z, Liu X, Ma S. The Roles of Mitochondria in Autophagic Cell Death. Cancer Biother. Radiopharm. 2016; 31(8):
  6. -276.
  7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket guide to COPD diagnosis, management and prevention: a guide for health care professionals. 2016. Available at: http://www.goldcopd.org/ (accessed 02/07/09).
  8. Gnudi L, Coward RJ, Long DA. Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. Trends Endocrinolog. Metab. 2016; 27(11): 820-830.
  9. Zhu J, Wang H, Chen F. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. Free Radic Biol. Med. 2016; 99: 544-556.
  10. Kurundkar A, Thannickal VJ. Redox mechanisms in age-related lung fibrosis. Redox Biol. 2016; 9: 67-76.
  11. Redza-Dutordoir M, Averill-Bates D. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. Biophys. Acta. 2016; 1863(12): 2977-2992.
  12. Regina C, Panatta E, Candi E. Vascular ageing and endothelial cell senescence: Molecular mechanisms of physiology and diseases. Mech. Ageing Dev. 2016; l(159): 14-21.
Publication:
«World of Medicine and Biology» Vol. 15 No. 67 (2019) , с. 121-125
УДК 616-08+615.276+616.24+616.12-009.72